Statins for the prevention of venous thromboembolism? a narrative review.

Amikar Sehdev, Nathan Wanner, Robert C. Pendleton

Research output: Contribution to journalReview article

Abstract

Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is a substantial public health problem. The majority of VTE events are associated with transient periods of heightened risk, such as prolonged hospitalization, undergoing major surgery, experiencing trauma or lower extremity immobility, use of oral contraceptives, or having active cancer. Although pharmacologic thromboprophylaxis agents (eg, unfractionated heparin, low-molecular-weight heparins, warfarin, and novel oral anticoagulants) are effective, they remain underused, with concerns about increased bleeding risk often cited as a reason. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (ie, statins), although used primarily for lipid lowering and arterial thrombosis risk reduction, have pleiotrophic effects that affect coagulation and inflammation, and do not increase bleeding risk. There is emerging evidence to suggest that through these pleiotrophic effects, statins may be effective in reducing the incidence of VTE. This article summarizes the literature with regard to statins' effect on VTE and suggests that additional investigations are needed to assess a potential adjunctive role for primary VTE thromboprophylaxis.

Original languageEnglish (US)
Pages (from-to)13-18
Number of pages6
JournalHospital practice (1995)
Volume40
Issue number3
StatePublished - Aug 2012
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Venous Thromboembolism
Hemorrhage
Low Molecular Weight Heparin
Warfarin
Risk Reduction Behavior
Oral Contraceptives
Pulmonary Embolism
Venous Thrombosis
Anticoagulants
Heparin
Lower Extremity
Oxidoreductases
Hospitalization
Thrombosis
Public Health
Inflammation
Lipids
Incidence
Wounds and Injuries

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Statins for the prevention of venous thromboembolism? a narrative review. / Sehdev, Amikar; Wanner, Nathan; Pendleton, Robert C.

In: Hospital practice (1995), Vol. 40, No. 3, 08.2012, p. 13-18.

Research output: Contribution to journalReview article

Sehdev, Amikar ; Wanner, Nathan ; Pendleton, Robert C. / Statins for the prevention of venous thromboembolism? a narrative review. In: Hospital practice (1995). 2012 ; Vol. 40, No. 3. pp. 13-18.
@article{b2c1b5500cee474796c074f2ceef1d31,
title = "Statins for the prevention of venous thromboembolism? a narrative review.",
abstract = "Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is a substantial public health problem. The majority of VTE events are associated with transient periods of heightened risk, such as prolonged hospitalization, undergoing major surgery, experiencing trauma or lower extremity immobility, use of oral contraceptives, or having active cancer. Although pharmacologic thromboprophylaxis agents (eg, unfractionated heparin, low-molecular-weight heparins, warfarin, and novel oral anticoagulants) are effective, they remain underused, with concerns about increased bleeding risk often cited as a reason. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (ie, statins), although used primarily for lipid lowering and arterial thrombosis risk reduction, have pleiotrophic effects that affect coagulation and inflammation, and do not increase bleeding risk. There is emerging evidence to suggest that through these pleiotrophic effects, statins may be effective in reducing the incidence of VTE. This article summarizes the literature with regard to statins' effect on VTE and suggests that additional investigations are needed to assess a potential adjunctive role for primary VTE thromboprophylaxis.",
author = "Amikar Sehdev and Nathan Wanner and Pendleton, {Robert C.}",
year = "2012",
month = "8",
language = "English (US)",
volume = "40",
pages = "13--18",
journal = "Hospital practice (1995)",
issn = "2154-8331",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Statins for the prevention of venous thromboembolism? a narrative review.

AU - Sehdev, Amikar

AU - Wanner, Nathan

AU - Pendleton, Robert C.

PY - 2012/8

Y1 - 2012/8

N2 - Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is a substantial public health problem. The majority of VTE events are associated with transient periods of heightened risk, such as prolonged hospitalization, undergoing major surgery, experiencing trauma or lower extremity immobility, use of oral contraceptives, or having active cancer. Although pharmacologic thromboprophylaxis agents (eg, unfractionated heparin, low-molecular-weight heparins, warfarin, and novel oral anticoagulants) are effective, they remain underused, with concerns about increased bleeding risk often cited as a reason. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (ie, statins), although used primarily for lipid lowering and arterial thrombosis risk reduction, have pleiotrophic effects that affect coagulation and inflammation, and do not increase bleeding risk. There is emerging evidence to suggest that through these pleiotrophic effects, statins may be effective in reducing the incidence of VTE. This article summarizes the literature with regard to statins' effect on VTE and suggests that additional investigations are needed to assess a potential adjunctive role for primary VTE thromboprophylaxis.

AB - Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is a substantial public health problem. The majority of VTE events are associated with transient periods of heightened risk, such as prolonged hospitalization, undergoing major surgery, experiencing trauma or lower extremity immobility, use of oral contraceptives, or having active cancer. Although pharmacologic thromboprophylaxis agents (eg, unfractionated heparin, low-molecular-weight heparins, warfarin, and novel oral anticoagulants) are effective, they remain underused, with concerns about increased bleeding risk often cited as a reason. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (ie, statins), although used primarily for lipid lowering and arterial thrombosis risk reduction, have pleiotrophic effects that affect coagulation and inflammation, and do not increase bleeding risk. There is emerging evidence to suggest that through these pleiotrophic effects, statins may be effective in reducing the incidence of VTE. This article summarizes the literature with regard to statins' effect on VTE and suggests that additional investigations are needed to assess a potential adjunctive role for primary VTE thromboprophylaxis.

UR - http://www.scopus.com/inward/record.url?scp=84906292890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906292890&partnerID=8YFLogxK

M3 - Review article

VL - 40

SP - 13

EP - 18

JO - Hospital practice (1995)

JF - Hospital practice (1995)

SN - 2154-8331

IS - 3

ER -